An interventional study of Inosine pranobex in HIV Infections, sponsored by Newport Pharmaceuticals International. Completed at 1 site in United States. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Newport Pharmaceuticals International · Not applicable, Interventional, and Treatment
The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS. Secondly, to determine the effect of Isoprinosine in decreasing the severity and/or incidence of lesser opportunistic infections and/or other conditions associated with ARC.
Exclusion Criteria
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 1 month of study entry:
Prior Treatment:
Excluded within 1 month of study entry:
History of gout, uric acid urolithiasis, uric acid nephrolithiasis, or renal dysfunction.
Homosexual male patients with AIDS related complex (ARC).
Current IV drug abuse.
This study is completed, as verified in Jun 1989. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Newport Pharmaceuticals International